BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 30593739)

  • 1. Increased Response of Human T-Lymphocytes by Dendritic Cells Pulsed with HPV16E7 and Pleurotus sajor-caju-β-glucan (PBG).
    Roopngam PE
    Iran J Immunol; 2018 Dec; 15(4):246-255. PubMed ID: 30593739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention and treatment of cervical cancer by a single administration of human papillomavirus peptide vaccine with CpG oligodeoxynucleotides as an adjuvant in vivo.
    Yang Y; Che Y; Zhao Y; Wang X
    Int Immunopharmacol; 2019 Apr; 69():279-288. PubMed ID: 30743204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines.
    Bellone S; El-Sahwi K; Cocco E; Casagrande F; Cargnelutti M; Palmieri M; Bignotti E; Romani C; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    J Virol; 2009 Jul; 83(13):6779-89. PubMed ID: 19386711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fungal mannosylation enhances human papillomavirus 16 E7 therapeutic immunity against TC-1 tumors.
    Wang Z; Wei C; Zhang Y; Wang W; Zhou Z; Xiao G
    Oncol Rep; 2018 Jan; 39(1):425-432. PubMed ID: 29115562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Genetically Modified attenuated
    Jia YY; Tan WJ; Duan FF; Pan ZM; Chen X; Yin YL; Jiao XA
    Front Cell Infect Microbiol; 2017; 7():279. PubMed ID: 28706878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and evaluation of a multi-epitope DNA vaccine against HPV16.
    Zhu L; Cui X; Yan Z; Tao Y; Shi L; Zhang X; Yao Y; Shi L
    Hum Vaccin Immunother; 2024 Dec; 20(1):2352908. PubMed ID: 38780076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prophylactic and therapeutic efficacy of an attenuated Listeria monocytogenes-based vaccine delivering HPV16 E7 in a mouse model.
    Jia Y; Yin Y; Duan F; Fu H; Hu M; Gao Y; Pan Z; Jiao X
    Int J Mol Med; 2012 Dec; 30(6):1335-42. PubMed ID: 23027427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GTL001 and bivalent CyaA-based therapeutic vaccine strategies against human papillomavirus and other tumor-associated antigens induce effector and memory T-cell responses that inhibit tumor growth.
    Esquerré M; Momot M; Goubier A; Gonindard C; Leung-Theung-Long S; Misseri Y; Bissery MC
    Vaccine; 2017 Mar; 35(11):1509-1516. PubMed ID: 28196735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increase of human papillomavirus-16 E7-specific T helper type 1 response in peripheral blood of cervical cancer patients after radiotherapy.
    Delgado FG; Martínez E; Céspedes MA; Bravo MM; Navas MC; Cómbita Rojas AL
    Immunology; 2009 Apr; 126(4):523-34. PubMed ID: 18778290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineered outer membrane vesicle is potent to elicit HPV16E7-specific cellular immunity in a mouse model of TC-1 graft tumor.
    Wang S; Huang W; Li K; Yao Y; Yang X; Bai H; Sun W; Liu C; Ma Y
    Int J Nanomedicine; 2017; 12():6813-6825. PubMed ID: 28979120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
    Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
    Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human papillomavirus 16 L1-E7 chimeric virus like particles show prophylactic and therapeutic efficacy in murine model of cervical cancer.
    Sharma C; Dey B; Wahiduzzaman M; Singh N
    Vaccine; 2012 Aug; 30(36):5417-24. PubMed ID: 22717329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dendritic cell-based tumor vaccine for cervical cancer I: in vitro stimulation with recombinant protein-pulsed dendritic cells induces specific T cells to HPV16 E7 or HPV18 E7.
    Nonn M; Schinz M; Zumbach K; Pawlita M; Schneider A; Dürst M; Kaufmann AM
    J Cancer Res Clin Oncol; 2003 Sep; 129(9):511-20. PubMed ID: 12905010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intratumoral injection of therapeutic HPV vaccinia vaccine following cisplatin enhances HPV-specific antitumor effects.
    Lee SY; Kang TH; Knoff J; Huang Z; Soong RS; Alvarez RD; Hung CF; Wu TC
    Cancer Immunol Immunother; 2013 Jul; 62(7):1175-85. PubMed ID: 23615841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of therapeutic DNA vaccine potency by melatonin through inhibiting VEGF expression and induction of antitumor immunity mediated by CD8+ T cells.
    Baghban Rahimi S; Mohebbi A; Vakilzadeh G; Biglari P; Razeghi Jahromi S; Mohebi SR; Shirian S; Gorji A; Ghaemi A
    Arch Virol; 2018 Mar; 163(3):587-597. PubMed ID: 29149434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel "priming-boosting" strategy for immune interventions in cervical cancer.
    Liao S; Zhang W; Hu X; Wang W; Deng D; Wang H; Wang C; Zhou J; Wang S; Zhang H; Ma D
    Mol Immunol; 2015 Apr; 64(2):295-305. PubMed ID: 25575128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities.
    Santin AD; Bellone S; Palmieri M; Ravaggi A; Romani C; Tassi R; Roman JJ; Burnett A; Pecorelli S; Cannon MJ
    Gynecol Oncol; 2006 Mar; 100(3):469-78. PubMed ID: 16249018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of six cell penetrating peptides with different properties for in vitro and in vivo delivery of HPV16 E7 antigen in therapeutic vaccines.
    Shahbazi S; Bolhassani A
    Int Immunopharmacol; 2018 Sep; 62():170-180. PubMed ID: 30015237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immuno-Stimulating Peptide Derived from HMGB1 is More Effective Than the N-Terminal Domain of Gp96 as an Endogenous Adjuvant for Improvement of Protein Vaccines.
    Talebi S; Bolhassani A; Azad TM; Arashkia A; Modaresi MH
    Protein Pept Lett; 2017; 24(3):190-196. PubMed ID: 28000571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SA-4-1BBL as the immunomodulatory component of a HPV-16 E7 protein based vaccine shows robust therapeutic efficacy in a mouse cervical cancer model.
    Sharma RK; Srivastava AK; Yolcu ES; MacLeod KJ; Schabowsky RH; Madireddi S; Shirwan H
    Vaccine; 2010 Aug; 28(36):5794-802. PubMed ID: 20603135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.